<DOC>
	<DOCNO>NCT01677455</DOCNO>
	<brief_summary>The purpose study determine ganetespib ( STA-9090 ) effective treatment patient HER2+ triple negative breast cancer receive prior systemic treatment metastatic setting .</brief_summary>
	<brief_title>An Open-Label Multicenter Phase 2 Window Opportunity Study Evaluating Ganetespib Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Pathologically confirm diagnosis invasive breast cancer . Stage IV disease . Documented HER2 hormonal receptor status per protocol , ER/PR+ patient must refractory least one prior hormonal treatment . ECOG Performance status 01 . Measurable disease per RECIST ( 1.1 ) . Adequate hematological function per protocol . Adequate hepatic function per protocol . Adequate renal function per protocol . Negative serum pregnancy test study entry patient childbearing potential . Ability understand sign write consent comply study protocol . Presence active untreated CNS metastasis determine MRI/CT scan perform screen . Active malignancy MBC within last 5 year except adequately treat situ carcinoma cervix uteri basal squamous cell carcinoma skin . Bone site metastatic disease breast cancer . Prior radiotherapy area measurable disease . NOTE : Radiotherapy limit area sole site measurable disease allow , receive prior initiation ganetespib treatment . Patients must complete treatment recover acute treatmentrelated toxicity prior administration first dose ganetespib . Pregnancy lactation . Known serious cardiac illness . Uncontrolled intercurrent illness per protocol . Other severe acute chronic medical condition abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hsp90 inhibitor</keyword>
	<keyword>ganetespib</keyword>
	<keyword>STA 9090</keyword>
</DOC>